Pekin Hardy Strauss Inc. Cuts Position in Sanofi (NASDAQ:SNY)

Pekin Hardy Strauss Inc. lessened its holdings in Sanofi (NASDAQ:SNY) by 6.3% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 10,018 shares of the company’s stock after selling 679 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Sanofi were worth $486,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. TCTC Holdings LLC raised its holdings in shares of Sanofi by 28.0% in the 1st quarter. TCTC Holdings LLC now owns 960 shares of the company’s stock worth $47,000 after purchasing an additional 210 shares during the period. HB Wealth Management LLC raised its holdings in shares of Sanofi by 3.7% in the 2nd quarter. HB Wealth Management LLC now owns 6,166 shares of the company’s stock worth $299,000 after purchasing an additional 221 shares during the period. Wynn Capital LLC raised its holdings in shares of Sanofi by 4.5% in the 1st quarter. Wynn Capital LLC now owns 5,266 shares of the company’s stock worth $256,000 after purchasing an additional 226 shares during the period. Angeles Investment Advisors LLC raised its holdings in shares of Sanofi by 2.1% in the 4th quarter. Angeles Investment Advisors LLC now owns 12,029 shares of the company’s stock worth $598,000 after purchasing an additional 244 shares during the period. Finally, EP Wealth Advisors LLC raised its holdings in shares of Sanofi by 5.3% in the 4th quarter. EP Wealth Advisors LLC now owns 5,035 shares of the company’s stock worth $250,000 after purchasing an additional 255 shares during the period. Hedge funds and other institutional investors own 10.04% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on SNY. Argus lifted their price target on shares of Sanofi from $55.00 to $60.00 and gave the stock a “buy” rating in a report on Friday, July 26th. StockNews.com cut shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Wednesday, September 11th. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Hold” and an average target price of $57.50.

Sanofi Trading Down 0.7 %

Sanofi stock opened at $56.91 on Wednesday. The stock has a market cap of $144.14 billion, a P/E ratio of 28.60, a PEG ratio of 1.60 and a beta of 0.60. Sanofi has a fifty-two week low of $42.63 and a fifty-two week high of $58.97. The firm’s fifty day moving average price is $53.95 and its 200-day moving average price is $50.30. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, July 25th. The company reported $0.93 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.05. The firm had revenue of $10.75 billion for the quarter, compared to analysts’ expectations of $16.86 billion. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The business’s quarterly revenue was up 7.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.95 earnings per share. Equities research analysts forecast that Sanofi will post 4.25 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.